EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers

Filipe A Moura iD, Frederick K Kamanu, Stephen D Wiviott, Robert P Giugliano, Miriam S Udler, Jose C Florez, Patrick T Ellinor, Marc S Sabatine iD, Christian T Ruff, Nicholas A Marston

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16123 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Filipe A Moura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Diabetes Research Center, Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, American Heart Association, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the predictive value of a contemporary type 2 diabetes (T2D) polygenic score (PGS) in detecting incident diabetes across a range of diabetes risk factors. Materials and Methods We analysed participants in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial ( ClinicalTrials.gov , number NCT0176463), which compared the efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab versus placebo in lowering cardiovascular outcomes in participants with stable atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg/dL (1.8 mmol/L) or higher who were receiving statin therapy. Genetic risk was characterized using a previously validated T2D PGS based on ~1.2 million single‐nucleotide polymorphisms. PGS was analysed continuously and categorically as high (top 20% of the PGS) and low to intermediate (lower 80% of the PGS). The effect of evolocumab on incident diabetes in patients without diabetes at baseline was also assessed. HbA1c was measured at baseline and every 24 weeks thereafter, while FPG was measured at baseline, week 12, week 24 and every 24 weeks thereafter. Potential cases of incident diabetes were adjudicated centrally. Hazards ratios (HRs) for incident diabetes were adjusted for baseline characteristics and ancestry.

Results

Among 9388 participants, the mean age was 63 ± 9 years and 22.7% were women, with median HbA1c 39 mmol/mol (36 mmol/mol – 41 mmol/mol; 5.7% [5.4%–5.9%]) and mean body mass index (BMI) 28.7 ± 5 kg/m 2 . Diabetes developed in 690 participants (7.3%) during 2.3 years of median follow‐up. T2D PGS predicted incident T2D (HR per 1‐SD 1.22, 95% CI 1.14–1.32, p < 0.001). The rates of incident T2D in the high and low to intermediate genetic risk categories were 12.1% versus 6.8%, respectively (HR 1.43 95% CI 1.20–1.70, p < 0.001). Notably, high T2D genetic risk had greater predictive strength among individuals with lower HbA1c ( P ‐int = 0.0499) and lower BMI ( P ‐int = 0.004).

Conclusions

The T2D polygenic score serves as an independent predictor of incident diabetes, particularly among individuals with lower distribution of traditional risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HumansFemaleMaleMiddle AgedGenetic Predisposition to DiseaseRisk FactorsPolymorphism, Single NucleotideAgedIncidenceAntibodies, Monoclonal, HumanizedPCSK9 InhibitorsGlycated HemoglobinAnticholesteremic AgentsMultifactorial InheritanceHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9

Stichwörter der Autor:innen

PCSK9 inhibitionclinical trialgenetic epidemiologygenetic riskincident diabeteslipid‐lowering therapyrisk predictiontype 2 diabetes

Substanzen

evolocumabAntibodies, Monoclonal, HumanizedPCSK9 protein, humanPCSK9 InhibitorsGlycated HemoglobinAnticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9

Autor:innen und Institutionen

  • Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • VA Connecticut Healthcare System, West Haven, Connecticut, USA.
  • TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Center for Genomic Medicine and Diabetes Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Programs in Metabolism and Medical & Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Filipe A Moura, Marc S Sabatine

Förderung

  • Diabetes Research Center, Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania
  • American Heart Association
  • NHLBI NIH HHS
  • NIH HHS
  • European Union
  • National Heart, Lung, and Blood Institute
  • National Institutes of Health
  • European Commission

Zitieren

APA

Moura, F. A., Kamanu, F. K., Wiviott, S. D., Giugliano, R. P., Udler, M. S., Florez, J. C., Ellinor, P. T., Sabatine, M. S., Ruff, C. T., & Marston, N. A. (2025). Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16123

Vancouver

Moura FA, Kamanu FK, Wiviott SD, Giugliano RP, Udler MS, Florez JC, et al. Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16123

BibTeX
@article{Moura2025,
  author = {Moura, Filipe A and Kamanu, Frederick K and Wiviott, Stephen D and Giugliano, Robert P and Udler, Miriam S and Florez, Jose C and Ellinor, Patrick T and Sabatine, Marc S and Ruff, Christian T and Marston, Nicholas A},
  title = {Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16123}
}
Kostenlos starten →